Skip to menu Skip to content Skip to footer
Dr Andy Moore
Dr

Andy Moore

Email: 

Overview

Background

Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).

Availability

Dr Andy Moore is:
Not available for supervision
Media expert

Qualifications

  • Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
  • Doctor of Philosophy, University College London

Research interests

  • Acute Myeloid Leukaemia

  • Leukaemia

  • Blood Cancers

  • Paediatric Oncology

  • Childhood Cancer

  • Biobanking

Works

Search Professor Andy Moore’s works on UQ eSpace

94 works between 2007 and 2024

61 - 80 of 94 works

2017

Journal Article

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia

Charmsaz, S., Al-Ejeh, F., Yeadon, T. M., Miller, K. J., Smith, F. M., Stringer, B. W., Moore, A. S., Lee, F.-T., Cooper, L. T., Stylianou, C., Yarranton, G. T., Woronicz, J., Scott, A. M., Lackmann, M. and Boyd, A. W. (2017). EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia, 31 (8), 1779-1787. doi: 10.1038/leu.2016.371

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia

2016

Journal Article

Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors

Torchia, Jonathon, Golbourn, Brian, Feng, Shengrui, Ho, King Ching, Sin-Chan, Patrick, Vasiljevic, Alexandre, Norman, Joseph D., Guilhamon, Paul, Garzia, Livia, Agamez, Natalia R., Lu, Mei, Chan, Tiffany S., Picard, Daniel, de Antonellis, Pasqualino, Khuong-Quang, Dong-Anh, Planello, Aline C., Zeller, Constanze, Barsyte-Lovejoy, Dalia, Lafay-Cousin, Lucie, Letourneau, Louis, Bourgey, Mathieu, Yu, Man, Gendoo, Deena M. A., Dzamba, Misko, Barszczyk, Mark, Medina, Tiago, Riemenschneider, Alexandra N., Morrissy, A. Sorana, Ra, Young-Shin ... Huang, Annie (2016). Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell, 30 (6), 891-908. doi: 10.1016/j.ccell.2016.11.003

Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors

2016

Journal Article

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D. and Vormoor, J. (2016). A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood and Cancer, 64 (6) e26351, e26351. doi: 10.1002/pbc.26351

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

2016

Journal Article

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

Smith, Amanda M., Dun, Matthew D., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan, Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop and Verrills, Nicole M. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7 (30), 47465-47478. doi: 10.18632/oncotarget.10167

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

2016

Journal Article

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma

Nikbakht, Hamid, Panditharatna, Eshini, Mikael, Leonie G., Li, Rui, Gayden, Tenzin, Osmond, Matthew, Ho, Cheng-Ying, Kambhampati, Madhuri, Hwang, Eugene I., Faury, Damien, Siu, Alan, Papillon-Cavanagh, Simon, Bechet, Denise, Ligon, Keith L., Ellezam, Benjamin, Ingram, Wendy J., Stinson, Caedyn, Moore, Andrew S., Warren, Katherine E., Karamchandani, Jason, Packer, Roger J., Jabado, Nada, Majewski, Jacek and Nazarian, Javad (2016). Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 7 (1) 11185, 11185. doi: 10.1038/ncomms11185

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma

2016

Journal Article

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

Thompson, Eric M., Hielscher, Thomas, Bouffet, Eric, Remke, Marc, Luu, Betty, Gururangan, Sridharan, McLendon, Roger E., Bigner, Darell D., Lipp, Eric S., Perreault, Sebastien, Cho, Yoon-Jae, Grant, Gerald, Kim, Seung-Ki, Lee, Ji Yeoun, Rao, Amulya A. Nageswara, Giannini, Caterina, Li, Kay Ja Wai, Ng, Ho-Keung, Yao, Yu, Kumabe, Toshihiro, Tominaga, Teiji, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Low, David C. Y., Seow, Wan Tew, Chang, Kenneth T. E., Mora, Jaume, Pollack, Ian F., Hamilton, Ronald L. ... Taylor, Michael D. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology, 17 (4), 484-495. doi: 10.1016/S1470-2045(15)00581-1

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

2016

Journal Article

New brain tumor entities emerge from molecular classification of CNS-PNETs

Sturm, Dominik, Orr, Brent A., Toprak, Umut H., Hovestadt, Volker, Jones, David T. W., Capper, David, Sill, Martin, Buchhalter, Ivo, Northcott, Paul A., Leis, Irina, Ryzhova, Marina, Koelsche, Christian, Pfaff, Elke, Allen, Sariah J., Balasubramanian, Gnanaprakash, Worst, Babara C., Pajtler, Kristian W., Brabetz, Sebastian, Johann, Pascal D., Sahm, Felix, Reimand, Juri, Mackay, Alan, Carvalho, Diana M., Remke, Marc, Phillips, Joanna J., Perry, Arie, Cowdrey, Cynthia, Drissi, Rachid, Fouladi, Maryam ... Kool, Marcel (2016). New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell, 164 (5), 1060-1072. doi: 10.1016/j.cell.2016.01.015

New brain tumor entities emerge from molecular classification of CNS-PNETs

2016

Conference Publication

A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer.

Hennig, S., Kunarajah, K., Norris, R., Lobb, M., Charles, B., Pinkerton, R. and Moore, A. S. (2016). A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer.. World Conference of Pharmacometrics, Brisbane / Brisbane Convention Centre, 21-24 August 2016.

A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer.

2015

Journal Article

EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.

Charmsaz, Sara, Beckett, Kirrilee, Smith, Fiona M., Bruedigam, Claudia, Moore, Andrew S., Al-Ejeh, Fares, Lane, Steven W. and Boyd, Andrew W. (2015). EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.. PLoS One, 10 (6) e0130692, e0130692-e0130692. doi: 10.1371/journal.pone.0130692

EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.

2015

Journal Article

The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.

Foresto, Steven A., Youlden, Danny R., Baader, Peter D., Hallahan, Andrew R., Aitken, Joanne F. and Moore, Andrew S. (2015). The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.. Pediatric Blood and Cancer, 62 (9), 1664-1666. doi: 10.1002/pbc.25517

The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.

2015

Journal Article

Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia

Smith, Amanda M., Little, Erica B., Zivanovic, Andjelija, Hong, Priscilla, Liu, Alfred K. S., Burow, Rachel, Stinson, Caedyn, Hallahan, Andrew R. and Moore, Andrew S. (2015). Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia. Leukemia Research, 39 (4), 435-444. doi: 10.1016/j.leukres.2015.01.005

Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia

2015

Conference Publication

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Hahn, Christopher N., Babic, Milena, Schreiber, Andreas W., Kutyna, Monika M., Wee, L. Amilia, Brown, Anna L., Perugini, Michelle, Singhal, Deepak, Hiwase, Smita, Feng, Jinghua, Parker, Wendy T., Moore, Sarah, Bardy, Peter G., Saal, Russell, Marlton, Paula, Moore, Andrew S., Gonda, Thomas J., Leo, Paul, Branford, Susan, DAndrea, Richard J., Lewis, Ian D., Bik, Luen, Scott, Harnish S. and Hiwase, Devendra (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 5-8 December 2015. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood.V126.23.1644.1644

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

2014

Journal Article

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy

Bruedigam, C., Bagger, F.O., Heidel, F.H., Paine, Kuhn C., Guignes, S., Song, A., Austin, R., Vu, T., Lee, E., Riyat, S., Moore, A.S., Lock, R.B., Bullinger, L., Hill, G.R., Armstrong, S.A., Williams, D.A. and Lane, S.W. (2014). Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell, 15 (6), 775-790. doi: 10.1016/j.stem.2014.11.010

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy

2014

Journal Article

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

Roberts, K. G., Li, Y., Payne‑Turner, D., Harvey, R. C., Yang, Y.‑L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., Ma, J., Becksfort, J., Rusch, M., Chen, S.‑C., Easton, J., Cheng, J., Boggs, K., Santiago‑Morales, N., Iacobucci, I., Fulton, R. S., Wen, J., Valentine, M., Cheng, C., Paugh, S. W., Devidas, M., Chen, I.‑M., Reshmi, S., Smith, A., Hedlund, E. ... Mullighan, C. G. (2014). Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine, 371 (11), 1005-1015. doi: 10.1056/NEJMoa1403088

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

2014

Conference Publication

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

Bruedigam, Claudia, Bagger, Frederik Otzen, Heidel, Florian H., Kuhn, Catherine, Guignes, Solene, Song, Axia, Austin, Rebecca, Vu, Therese, Lee, Erwin M., Moore, Andrew S., Lock, Richard B., Bullinger, Lars, Hill, Geoff R. and Lane, Steven W. (2014). Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML). 56th Annual Meeting of the American Society of Hematology, San Francisco CA, United States, 06-09 December 2014. Washington, DC United States: American Society of Hematology.

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

2013

Journal Article

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Soosay Raj, Trisha A., Smith, Amanda M. and Moore, Andrew S. (2013). Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. International Journal of Nanomedicine, 8 (1), 4361-4369. doi: 10.2147/IJN.S54657

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

2013

Journal Article

BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Moore, Andrew S., Alonzo, Todd A., Gerbing, Robert B., Lange, Beverly J., Heerema, Nyla A., Franklin, Janet, Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S. and Meshinchi, Soheil (2013). BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood and Cancer, 61 (4), 647-652. doi: 10.1002/pbc.24822

BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

2013

Journal Article

Novel therapies for children with acute myeloid leukaemia

Moore, A. S., Kearns, P. R., Knapper, S., Pearson, A. D. J. and Zwaan, C. M. (2013). Novel therapies for children with acute myeloid leukaemia. Leukemia, 27 (7), 1451-1460. doi: 10.1038/leu.2013.106

Novel therapies for children with acute myeloid leukaemia

2012

Journal Article

Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

Bavetsias, Vassilios, Crumpler, Simon, Sun, Chongbo, Avery, Sian, Atrash, Butrus, Faisal, Amir, Moore, Andrew S., Kosmopoulou, Magda, Brown, Nathan, Sheldrake, Peter W., Bush, Katherine, Henley, Alan, Box, Gary, Valenti, Melanie, Brandon, Alexis de Haven, Raynaud, Florence I., Workman, Paul, Eccles, Suzanne A., Bayliss, Richard, Linardopoulos, Spiros and Blagg, Julian (2012). Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 55 (20), 8721-8734. doi: 10.1021/jm300952s

Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

2012

Journal Article

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns

Moore, A. S., Faisal, A., Gonzalez de Castro, D., Bavetsias, V., Sun, C., Atrash, B., Valenti, M., de Haven Brandon, A., Avery, S., Mair, D., Mirabella, F., Swansbury, J., Pearson, A. D. J., Workman, P., Blagg, J., Raynaud, F. I., Eccles, S. A. and Linardopoulos, S. (2012). Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns. Leukemia, 26 (7), 1462-1470. doi: 10.1038/leu.2012.52

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns

Supervision

Availability

Dr Andy Moore is:
Not available for supervision

Supervision history

Completed supervision

Media

Enquiries

Contact Dr Andy Moore directly for media enquiries about:

  • Childhood Cancer
  • Childhood Leukaemia

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au